Clinical trials: Single Women
Chronic Kidney Disease
Efficacy and Safety of the Ultrasound Stimulation Device NEFRONIX in Patients With Chronic Kidney Disease
This study is a prospective, multicenter, single-arm, open-label, non-randomized exploratory clinical trial designed to evaluate the safety and potential efficacy of an ultrasound stimulation device (NEFRONIX G-01) in patients…
- Trial name
- NCT07339098
- Testing
- Ultrasound Stimulation (NEFRONIX G-01)
- Volunteers
- 20 people
- Sponsor
- Anasonic
Healthy
Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers
Study to characterize the effects of two dose combinations of Tipranavir (TPV)/Ritonavir (RTV) (TPV 750 mg/RTV 200 mg and TPV 500 mg/RTV 100 mg), administered twice-daily, on the pharmacokinetics of Norethindrone-Ethinyl…
- Trial name
- NCT02245438
- Testing
- Tipranavir low dose, Tipranavir high dose, Ritonavir low dose
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Anemia, Renal Insufficiency, Chronic
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable…
- Trial name
- NCT03552393
- Testing
- Mircera
- Where
- 22 sites in United States, France and 5 more
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Interstitial Cystitis, Bladder Pain Syndrome
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and…
- Trial name
- NCT05737121
- Testing
- VNX001, Lidocaine, Heparin
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vaneltix Pharma, Inc.
Acute Kidney Injury, Fluid Overload
Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.
The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system.
- Trial name
- NCT04608149
- Testing
- Carpediem System
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mozarc Medical US LLC
Contraception
Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)
This study is a Phase III, multicenter, open-label, single-arm clinical trial designed to evaluate the contraceptive efficacy and safety of a new formulation containing N0999 in women of childbearing potential.
- Trial name
- LUNA (NCT07714616)
- Testing
- Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg
- Where
- Brazil
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Healthy
Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components
This Phase I trial in healthy, post-menopausal women is designed as a double-blind, placebo-controlled, randomized, ascending single-dose safety trial.
- Trial name
- NCT00453297
- Testing
- MF101
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bionovo
Mass Balance Recovery
Study in Healthy Adult Female Subjects
An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] D-0502 Following Single Oral Dose Administration
- Trial name
- NCT05339633
- Testing
- [14C]-D-0502
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Type 2 Diabetes
Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
The objective of this study is to evaluate the relative bioavailability, and the rate and extent of absorption of bromocriptine in male and female children and adolescent Type 2 Diabetes Mellitus patients, aged 10 to less than…
- Trial name
- NCT02078440
- Testing
- Bromocriptine mesylate
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- VeroScience
Cervical Cancer
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
This study was an open, single-arm, enriched, multicenter Phase II study.
- Trial name
- NCT06226350
- Testing
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Renal Impairment, Healthy Volunteers
A Study of TAK-279 in Adults With or Without Kidney Problems
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with kidney problems compared to participants without kidney problems.
- Trial name
- NCT05992155
- Testing
- TAK-279
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the…
- Trial name
- NCT01181726
- Testing
- Estradiol/Norethindrone acetate, Activella®
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
To assess the safety of the administration of the drug (CAT-354) in healthy Japanese subjects.
- Trial name
- NCT01093040
- Testing
- CAT-354, CAT 354
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Severe Renal Impairment, Healthy
A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)
The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
- Trial name
- NCT07734610
- Testing
- Nemtabrutinib
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Disease, Chronic Kidney Disease
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis.
- Trial name
- NCT00096915
- Testing
- Darbepoetin Alfa
- Volunteers
- 110 people
- Sponsor
- Amgen
Healthy
Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers
The objective of the present study was to obtain information about safety, tolerability and pharmacokinetics of BIBN 4096 BS after single subcutaneous administration of increasing doses in healthy male and female volunteers
- Trial name
- NCT02194348
- Testing
- BIBN 4096 BS - in single rising doses
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
- Trial name
- NCT06345755
- Testing
- VX-407, Midazolam
- Where
- 2 sites in United States, Canada
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.